Edward Carr

CIK: 0001273351

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (62.5%)

Position reduction

Option Exercises (M)4 (25.0%)

Derivative conversions

Awards (A)2 (12.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DNTH

Dianthus Therapeutics, Inc. /DE/

Officer

Discretionary Trading P&L

Holdings

Transaction History (16 total)

DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 17, 2026
Exercise(M)
Direct
20K shares at avg. $17.88$358K
DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 17, 2026
Sale(S)
Direct
7.9K shares at avg. $100.43$796K
DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 17, 2026
Sale(S)
Direct
6.8K shares at avg. $101.37$686K
DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 17, 2026
Sale(S)
Direct
3.5K shares at avg. $102.39$358K
DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 17, 2026
Sale(S)
Direct
1.1K shares at avg. $103.20$114K
DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 17, 2026
Sale(S)
Direct
700 shares at avg. $104.39$73K
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Sale(S)
Direct
200 shares at avg. $83.38$17K
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Sale(S)
Direct
300 shares at avg. $85.53$26K
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Exercise(M)
Direct
16.2K shares at avg. $17.88$289K
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Exercise(M)
Direct
17.5K shares at avg. $22.07$386K
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Exercise(M)
Direct
10K shares at avg. $21.77$218K
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Sale(S)
Direct
15.9K shares at avg. $80.71$1.3M
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Sale(S)
Direct
23.5K shares at avg. $81.75$1.9M
DNTH
Dianthus Therapeutics, Inc. /DE/
Mar 12, 2026
Sale(S)
Direct
3.9K shares at avg. $82.66$319K
DNTH
Dianthus Therapeutics, Inc. /DE/
Feb 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
55K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
60K shares-

		Type	Shares	Price		Ownership
Sep 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	20,000	$17.88	$357,600	Direct
Sep 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	7,928	$100.43	$796,209	Direct
Sep 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	6,771	$101.37	$686,376	Direct
Sep 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	3,501	$102.39	$358,467	Direct
Sep 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	1,100	$103.20	$113,520	Direct
Sep 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	700	$104.39	$73,073	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	200	$83.38	$16,676	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	300	$85.53	$25,659	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	16,182	$17.88	$289,334	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	17,500	$22.07	$386,225	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	10,000	$21.77	$217,700	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	15,852	$80.71	$1,279,415	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	23,465	$81.75	$1,918,264	Direct
Mar 12, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	3,865	$82.66	$319,481	Direct
Feb 3, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	55,000	-	-	Direct
Feb 3, 2025	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	60,000	-	-	Direct

1-16 of 16 transactions

About CARR EDWARD

CARR EDWARD (SEC CIK 0001273351) files insider reports with the SEC as CHIEF ACCOUNTING OFFICER of Dianthus Therapeutics, Inc. /DE/ (DNTH).

Signal8 holds 4 ownership filings by CARR EDWARD, all Form 4s, filed between Feb 4, 2025 and Sep 18, 2026. Those filings report 16 transactions, from Feb 3, 2025 to Sep 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on CARR EDWARD's filings is in NEW YORK, NY.

Recent filings by CARR EDWARD

Sep 17, 2026: Option exercise of DNTH shares (Form 4, code M).
Sep 17, 2026: Open-market sales of DNTH shares (5 lines, Form 4, code S).
Mar 12, 2026: Open-market sales of DNTH shares (2 lines, Form 4, code S).
Mar 12, 2026: Option exercises of DNTH shares (3 lines, Form 4, code M).
Mar 12, 2026: Open-market sales of DNTH shares (3 lines, Form 4, code S).

Other insiders filing for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Randhawa Simrat, EVP, Head of R&D
Read Simon, Director
Veness Adam M, SVP, General Counsel and Sec.
McGeorge Anne, Director
Garcia Marino, CEO AND PRESIDENT
Savitz Ryan, EVP, CFO & CBO

How to read Form 4 transaction codes